Current stock page

Catalysts

URGN Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

URGNUroGen Pharma Ltd.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$26.18−$0.21 (−0.80%)

Latest quote

  • Momentum
    40
  • Value
    64
  • Quality
    68
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 1, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 53/100

Momentum 40/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 17.29%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 40/100AIQ Edge 5/10 In Line With Peers
Beat rate
25%
2 of 8 reported periods
Average surprise
-21.6%
Across covered historical reports
Latest result
-128.4%
Nov 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 4, 2026—$0.11-$0.03-128.4%$89.92M$89M
Aug 5, 2026—-$0.27-$0.28-5.7%$63.55M$72.46M
May 6, 2026—-$0.56-$0.47+16.1%$44.83M$50.96M
Mar 2, 2026—-$0.52-$0.54-4.2%$39.91M$37.84M
Nov 6, 2025—-$0.72-$0.69+4.2%$40.13M$27.48M
Aug 7, 2025—-$0.82-$1.05-28.0%$33.57M$24.22M
May 12, 2025—-$0.83-$0.92-10.8%$23.26M$20.25M
Mar 10, 2025—-$0.69-$0.80-15.9%$23.34M$24.57M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
7
Buy
1
Hold
12-month analyst target
$58.00
+121.54% versus current price
Based on 8 analyst observations. Targets are estimates, not predictions.
Low target
$56.00
+113.90% vs latest price
Average target
$58.00
+121.54% vs latest price
High target
$60.00
+129.18% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 1, 2027

Next known earnings or reporting date.

EPS estimate$0.41

Current analyst expectation for the upcoming report.

Revenue estimate$107.09M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score40

Where event reaction would show up first.

AIQ score53/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
8
Average target
$58.00
Target upside
121.54%
Target range
$56.00 - $60.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
1
Neutral
2
Negative
1
seekingalpha.com · Nov 4, 2026

UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript

UroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call November 4, 2026 10:00 AM ESTCompany ParticipantsVincent Perrone - Senior Director of Investor...

gurufocus.com · Oct 19, 2026

UroGen Pharma (URGN) FDA Accepts Marketing Application for UGN-103 Bladder Cancer Treatment

On October 19, 2026, UroGen Pharma Ltd (NASDAQ: URGN) announced that the U.S. Food and Drug Administration (FDA) has accepted its marketing application for UGN-

seekingalpha.com · Oct 13, 2026

UroGen Pharma Stock: An Emerging GARP Stock (NASDAQ:URGN)

UroGen Pharma (URGN) stock dipped 30% after a 208% rally—see why Zusduri’s launch, reimbursement, and patents could fuel growth.

rttnews.com · Aug 20, 2026

UroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics

Shares of UroGen Pharma Ltd. (URGN) are falling about 5 percent in Thursday morning trading after the company entered into an equity investment agreement and a strategic Option and Research License Agreement with IntraGel Therapeutics.

Open full news and sentiment

URGN Catalysts FAQ

What are the next catalysts for URGN stock?

URGN's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move URGN stock?

Upcoming events that could move URGN include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could URGN's next earnings report affect the stock?

URGN's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive URGN stock higher?

URGN could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt URGN stock?

URGN could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.